Yesterday, Coherus Biosciences Inc (NASDAQ:CHRS) received a Complete Response Letter (CRL) from the FDA for its Biologics License Application (BLA) on CHS-1701, a …
Coherus Biosciences Inc (NASDAQ:CHRS) investors are wildly disappointed today following the news that the FDA has issued a complete response letter (CRL) for its …
Quick SPDR S&P 500 ETF Trust (NYSE ARCA:SPY) forecast update: Back on November 10th 2014 we predicted a spring 2015 high of 2181 …
